Search results
The Zacks Analyst Blog Highlights AstraZeneca, Qualcomm, FedEx, American International and Baker...
Zacks via Yahoo Finance· 1 day agoEvery day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and...
AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 7 days agoAstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript April 25, 2024 AstraZeneca PLC misses...
Astrazeneca plc ADR (AZN) Has A Gold Mine On Its Hands – Stocks Register
Stocks Register· 5 days agoAstrazeneca plc ADR (NASDAQ:AZN) at last check was buoying at $76.06 on Thursday, May 02, with a fall of -0.46% from its closing price on previous day.
ANGLE announces second assay with AstraZeneca as it deepens relationship with pharma giant
Proactive Investors· 4 days agoANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive Andrew Newland joins Proactive's Stephen Gunnion...
ANGLE teams up with AstraZeneca on a second assay
Proactive Investors· 4 days agoANGLE PLC (AIM:AGL, OTCQX:ANPCY), a leader in liquid biopsy technology, has signed a supplier agreement with AstraZeneca PLC (LSE:AZN) to develop an...
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032
WTNH-TV New Haven· 4 days ago(NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA),...
Vanguard Health Care Fund's Strategic Moves in Q1 2024: A Focus on Pfizer Inc
GuruFocus.com via Yahoo Finance· 4 days agoThe holdings are predominantly concentrated in the Healthcare, Consumer Defensive, and Financial...
Obesity drug rivals aim to unseat Zepbound, Ozempic - Indianapolis Business Journal
Indianapolis Business Journal· 4 days agoInsatiable demand for weight-loss drugs has made the market so feverish that any positive mention of...
Novo Slides as Amgen Fuels Obesity Drug Competition Fears
Bloomberg via Yahoo Finance· 4 days ago(Bloomberg) -- Novo Nordisk A/S shares fell as a US rival’s comments on an experimental obesity drug...
Novo’s Blockbuster Ozempic Among FTC’s Latest Patent Targets
Bloomberg Law· 7 days agoOzempic and Victoza are among 20 branded drugs the Federal Trade Commission is targeting as it challenges more than 300 “junk patent listings” in the FDA’s registry of approved drugs in an effort ...